Biomedical subjects

S Varia

Publications and source records attributed to S Varia.

3 recordsLinked to original sources

PubMed1993

Topical treatment with BV-araU of immunosuppressed and immunocompetent shaved mice cutaneously infected with herpes simplex virus type 1.

Effect of topical treatments with BV-araU was tested in cutaneous infections of shaved Balb/c mice with herpes simplex virus type 1. Evolution of zosteriform skin lesions associated with infection with a low virulent KOS(S) strain was almost completely suppressed by treatments with 5% BV-araU cream given 4 times daily for 5 days starting 1 day after inoculation. This effect was equivalent to that of Zovirax Cream including 5% acyclovir. One percent BV-araU cream was also effective in inhibiting progression of symptoms, while 0.2% cream was not effective. Five percent BV-araU cream significantly suppressed progression of skin lesion even if initiation of treatment was delayed to 2 days after infection. However, the efficacy was diminished by further delay in starting treatment. The effect of BV-araU cream was also evident during infection of immunosuppressed mice. Virus titers in the skin tissue encompassing the inoculation site of mice decreased the day after the first treatment. In the lower flank site, virus replication was almost completely suppressed by the treatment beginning 1 day postinfection. Topical application of BV-araU may be useful therapy for HSV-1 infections in humans, including immunocompromised patients.

Administration, Topical↗

PubMedDate not supplied

Aztreonam for injection (lyophilized): development of an automated solution batching process utilizing volumetric powder feeders.

As part of a commitment to fully automate the manufacture of a lyophilized dosage form of Azactam (Aztreonam for Injection), an automated solution batching procedure was developed. The lyophilization process requires solution batching of Aztreonam and L-arginine, the two constituents of the product. To avoid preblending of aztreonam and L-arginine prior to dissolution, a batching process was developed which makes use of two separate volumetric powder feeders. In conjunction with a feedback pH control system, these powder feeders provided for (a) a faster batching process, (b) a tight control of solution pH during batching, (c) a failsafe system to prevent operator error and equipment malfunction. Data are presented correlating bulk densities of various powders with feeder output along with solution pH profiles determined using the manual mode and the automated feedback pH control system.

Automation↗

PubMedDate not supplied

Development of a stable single-vial formulation for a new technetium complex using bilayer lyophilization.

The interaction between different components used in the preparation of a new radiodiagnostic agent, BMS-181321, was overcome by its lyophilization as a bilayered product. BMS-181321 is composed of a nitroimidazole ligand BMS-181032, that is complexed with technetium-99m just before it is used in radionuclide imaging studies. Stannous chloride is required to reduce technetium from the +7 to the +5 oxidation state before it can be complexed by the ligand. Because BMS-181032 is unstable in the presence of stannous chloride (when mixed in the liquid or solid state), the two components must be contained in separate vials. A bilayered lyophile was manufactured, containing the ligand and stannous chloride in separate layers in a single vial. The bilayered product was manufactured by first filling a solution of the ligand into a vial and freezing the solution. A solution containing stannous chloride was then filled into the same vial on top of the frozen layer of ligand, and this second layer was also frozen. The two frozen layers were then lyophilized to a dry solid cake. The resulting bilayered product showed stability comparable to that seen when the ligand and the reducing agent were contained in separate vials. The separation provided by the layering was sufficient to prevent any significant interaction between the reducing agent and the ligand.

Chemistry, Pharmaceutical↗